ZA200401302B - Combinations comprising cox-2 inhibitors and aspirin. - Google Patents

Combinations comprising cox-2 inhibitors and aspirin.

Info

Publication number
ZA200401302B
ZA200401302B ZA200401302A ZA200401302A ZA200401302B ZA 200401302 B ZA200401302 B ZA 200401302B ZA 200401302 A ZA200401302 A ZA 200401302A ZA 200401302 A ZA200401302 A ZA 200401302A ZA 200401302 B ZA200401302 B ZA 200401302B
Authority
ZA
South Africa
Prior art keywords
aspirin
cox
inhibitors
combinations
Prior art date
Application number
ZA200401302A
Other languages
English (en)
Inventor
Alberto Gimona
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200401302B publication Critical patent/ZA200401302B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200401302A 2001-10-11 2004-02-18 Combinations comprising cox-2 inhibitors and aspirin. ZA200401302B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0124459.9A GB0124459D0 (en) 2001-10-11 2001-10-11 Organic compounds

Publications (1)

Publication Number Publication Date
ZA200401302B true ZA200401302B (en) 2005-01-04

Family

ID=9923664

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200401302A ZA200401302B (en) 2001-10-11 2004-02-18 Combinations comprising cox-2 inhibitors and aspirin.

Country Status (19)

Country Link
US (2) US20040235802A1 (es)
EP (1) EP1435968A1 (es)
JP (1) JP2005505606A (es)
KR (1) KR20040044891A (es)
CN (1) CN1625405A (es)
AU (1) AU2006249254A1 (es)
BR (1) BR0213181A (es)
CA (1) CA2458981A1 (es)
CO (1) CO5570661A2 (es)
GB (1) GB0124459D0 (es)
HU (1) HUP0401854A2 (es)
IL (1) IL160620A0 (es)
MX (1) MXPA04003365A (es)
NO (1) NO20041432L (es)
NZ (1) NZ532158A (es)
PL (1) PL369005A1 (es)
RU (1) RU2004114560A (es)
WO (1) WO2003033001A1 (es)
ZA (1) ZA200401302B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US7338971B2 (en) 2001-08-30 2008-03-04 El-Naggar Mawaheb M Treatment of inflammatory, cancer, and thrombosis disorders
ATE419840T1 (de) 2002-04-09 2009-01-15 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
JP2006501161A (ja) 2002-06-11 2006-01-12 ニトロメッド インク． ニトロソ化および／またはニトロシル化シクロオキシゲナーゼ−２選択的阻害剤、組成物ならびに使用方法
JP2007519641A (ja) * 2004-01-27 2007-07-19 メルク フロスト カンパニー 血栓性心血管イベントの危険がある患者におけるシクロオキシゲナーゼ−２に媒介される疾患又は病態を治療するための併用療法
CA2609618C (en) * 2005-05-24 2016-01-05 Flamel Technologies Novel acetylsalicylic acid formulations
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
CN101257800B (zh) * 2005-07-18 2012-07-18 好利用医疗公司 包含法莫替丁和布洛芬的药物
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US8067033B2 (en) * 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US20100297224A1 (en) * 2006-08-31 2010-11-25 Horizon Therapeutics, Inc. NSAID Dose Unit Formulations with H2-Receptor Antagonists and Methods of Use
US9757529B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN104173359B (zh) * 2014-09-05 2017-05-03 罗国安 一种降低罗非考昔副作用的消炎镇痛复方药物及其应用
WO2018167447A1 (en) * 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants
US10272107B2 (en) * 2017-09-05 2019-04-30 Kenneth O. Russell Method for treating inflammatory brain disorders and traumatic brain injury
US10586872B2 (en) * 2018-07-03 2020-03-10 International Business Machines Corporation Formation of wrap-around-contact to reduce contact resistivity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743596A (en) * 1987-06-16 1988-05-10 Lapin Alfred R Anti-arthritic preparation
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
CN1203852C (zh) * 1999-12-08 2005-06-01 法马西亚公司 维得克西组合物
GB0002336D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
US8680081B2 (en) * 2000-08-29 2014-03-25 Peter Van Patten Prophylactic treatment of migraine

Also Published As

Publication number Publication date
GB0124459D0 (en) 2001-12-05
KR20040044891A (ko) 2004-05-31
PL369005A1 (en) 2005-04-18
AU2006249254A1 (en) 2007-01-04
US20080027032A1 (en) 2008-01-31
JP2005505606A (ja) 2005-02-24
US20040235802A1 (en) 2004-11-25
RU2004114560A (ru) 2005-05-20
MXPA04003365A (es) 2004-07-23
BR0213181A (pt) 2004-08-31
IL160620A0 (en) 2004-07-25
CA2458981A1 (en) 2003-04-24
WO2003033001A1 (en) 2003-04-24
HUP0401854A2 (hu) 2004-12-28
NO20041432D0 (no) 2004-04-05
NO20041432L (no) 2004-06-28
NZ532158A (en) 2006-04-28
CO5570661A2 (es) 2005-10-31
EP1435968A1 (en) 2004-07-14
CN1625405A (zh) 2005-06-08

Similar Documents

Publication Publication Date Title
MXPA03005298A (es) Inhibidores de girasa y usos de los mismos.
ZA200204390B (en) Caspase inhibitors and uses thereof.
MXPA03008177A (es) Inhibidores de metaloproteinasa..
MXPA03008180A (es) Inhibidores de metaloproteinasa.
AP2005003251A0 (en) New spirocondensed quinazolinones and their use asphosphodiesterase inhibitors.
MXPA03007310A (es) Derivados de ftalazinona piperidino como inhibidores pde4.
ZA200401302B (en) Combinations comprising cox-2 inhibitors and aspirin.
MXPA03008183A (es) Inhibidores de metaloproteinasa.
GB0129437D0 (en) Server and units
GB0114014D0 (en) Compostion and use
GB2376073B (en) Fluid-gauging systems and methods
EP1643961A4 (en) COX -2 INHIBITORS AND FAAH
MXPA03007596A (es) Lacas de poliuretano de 1c de secado al horno y su uso.
GB0131013D0 (en) Food information system and device
GB0109278D0 (en) Enzyme inhibitors
GB0130624D0 (en) Centre finding ruler-CENTERULE
ZA200200611B (en) Caspase inhibitors and uses thereof.
AU2002328342A1 (en) Kinase inhibitors and the use thereof
ZA200204418B (en) Handling mechanism and method.
ZA200003399B (en) Inhibitors.
ZA200003398B (en) Inhibitors.
GB0108872D0 (en) Hedgehog and notch
AU2002259301A1 (en) Caspase inhibitors and uses thereof
GB0102194D0 (en) Enzyme inhibitors
GB0109145D0 (en) Enzyme inhibitors